×

News publications and other organizations are encouraged to reuse Direct Relief-published content for free under a Creative Commons License (Attribution-Non-Commercial-No Derivatives 4.0 International), given the republisher complies with the requirements identified below.

When republishing:

  • Include a byline with the reporter’s name and Direct Relief in the following format: "Author Name, Direct Relief." If attribution in that format is not possible, include the following language at the top of the story: "This story was originally published by Direct Relief."
  • If publishing online, please link to the original URL of the story.
  • Maintain any tagline at the bottom of the story.
  • With Direct Relief's permission, news publications can make changes such as localizing the content for a particular area, using a different headline, or shortening story text. To confirm edits are acceptable, please check with Direct Relief by clicking this link.
  • If new content is added to the original story — for example, a comment from a local official — a note with language to the effect of the following must be included: "Additional reporting by [reporter and organization]."
  • If republished stories are shared on social media, Direct Relief appreciates being tagged in the posts:
    • Twitter (@DirectRelief)
    • Facebook (@DirectRelief)
    • Instagram (@DirectRelief)

Republishing Images:

Unless stated otherwise, images shot by Direct Relief may be republished for non-commercial purposes with proper attribution, given the republisher complies with the requirements identified below.

  • Maintain correct caption information.
  • Credit the photographer and Direct Relief in the caption. For example: "First and Last Name / Direct Relief."
  • Do not digitally alter images.

Direct Relief often contracts with freelance photographers who usually, but not always, allow their work to be published by Direct Relief’s media partners. Contact Direct Relief for permission to use images in which Direct Relief is not credited in the caption by clicking here.

Other Requirements:

  • Do not state or imply that donations to any third-party organization support Direct Relief's work.
  • Republishers may not sell Direct Relief's content.
  • Direct Relief's work is prohibited from populating web pages designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
  • Advance permission is required to translate Direct Relief's stories into a language different from the original language of publication. To inquire, contact us here.
  • If Direct Relief requests a change to or removal of republished Direct Relief content from a site or on-air, the republisher must comply.

For any additional questions about republishing Direct Relief content, please email the team here.

HIV/AIDS Care

Issues & Solutions

Over the past decade, remarkable progress has been made in the global response to the HIV/AIDS epidemic. Access to HIV prevention, testing and counseling, and care and treatment has expanded dramatically in low- and middle-income countries.

Quick Facts

Direct Relief is focused on providing diagnostic supplies, medicines, and medical equipment to improve care for people living with or at risk of HIV infection.


Direct Relief equips front-line healthcare providers with supplies to provide HIV testing, treatment, and support for people living with or at risk of HIV infection.


Direct Relief is collaborating with ministries of health and nongovernmental organizations internationally to expand access to HIV prevention and care.

HIV/AIDS Prevention and Care

While there has been a great deal of success, still far too many people are becoming infected with HIV, getting sick, and dying. In 2018, approximately 37.9 million people across the globe were living with HIV. A total of 1.7 million people were newly infected with HIV in 2018, and of those eligible for antiretroviral treatment, only 62 percent received the treatment they needed.

Treating Opportunistic Infections in People Living with HIV/AIDS

In 2010, Direct Relief became the implementing partner for the Diflucan® Partnership Program, a Pfizer global initiative that makes available Diflucan® to support treatment of opportunistic infections for people living with HIV. Diflucan® (fluconazole) is an essential anti-fungal medicine which has an important place in many National HIV/AIDS treatment programs. The Diflucan Partnership Program targets two opportunistic infections—esophageal candidiasis and cryptococcal meningitis—serious conditions with painful symptoms, and in the case of cryptococcal meningitis, can be life-threatening if gone untreated.

Diflucan® helps people living with HIV manage their opportunistic infections and promotes their ability to live more healthy, productive lives.

Giving is Good Medicine

You don't have to donate. That's why it's so extraordinary if you do.